What's New

Last Posted: Mar 21, 2019

• A Randomized Controlled Intervention to Promote Readiness to Genetic Counseling for Breast Cancer Survivors.
  Kasting Monica L et al. Psycho-oncology 2019 Mar
• Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
  Franceschini Gianluca et al. Annali italiani di chirurgia 2019 901-2
• Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
  Dinan Michaela A et al. Journal of the National Comprehensive Cancer Network : JNCCN 2019 Mar 17(3) 245-254
• Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
  Ow Samuel Guan Wei et al. PloS one 2019 14(3) e0213746
• Does family communication matter? Exploring knowledge of breast cancer genetics in cancer families.
  Himes Deborah O et al. Journal of community genetics 2019 Mar
• Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease.
  Puzhko Svetlana et al. Public health reviews 2019 402
• Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer.
  Yu Chengxiao et al. Breast cancer research and treatment 2019 Mar
• Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report.
  Seppälä Toni T et al. Hereditary cancer in clinical practice 2019 178
• Identifying Women at High Risk for Breast Cancer Using Data From the Electronic Health Record Compared With Self-Report.
  Jiang Xinyi et al. JCO clinical cancer informatics 2019 Mar (3) 1-8
• A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
  Risi Emanuela et al. Breast cancer research and treatment 2018 Jul 170(2) 329-341
• A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
  Rudolph M et al. Breast cancer research and treatment 2018 Jun 169(3) 457-467
• Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
  Clifton Katherine et al. Breast cancer research and treatment 2018 Jul 170(1) 101-109
• BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
  Wunderle Marius et al. Breast cancer research and treatment 2018 Aug 171(1) 85-94
• Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
  Li Minghui et al. Breast cancer research and treatment 2018 Jul 170(2) 257-270
• New emerging roles of microRNAs in breast cancer.
  Mandujano-Tinoco Edna Ayerim et al. Breast cancer research and treatment 2018 Sep 171(2) 247-259